- Home
- GROW vs HOWL Comparison
GROW vs HOWL Comparison
Compare GROW & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GROW | HOWL |
|---|---|---|
| Founded | 1968 | 2017 |
| Country | United States | United States |
| Employees | 24 | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.0M | 30.7M |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GROW | HOWL |
|---|---|---|
| Price | $2.62 | $0.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 18.0K | ★ 482.0K |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.53% | N/A |
| EPS Growth | N/A | ★ 18.40 |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $23,850,609.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.67 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.16 | $0.50 |
| 52 Week High | $3.65 | $2.23 |
Technical Indicators
Market Signals| Indicator | GROW | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 48.64 | 30.00 |
| Support Level | $2.33 | N/A |
| Resistance Level | $2.73 | $0.75 |
| Average True Range (ATR) | 0.08 | 0.08 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 43.49 | 3.53 |
Price Performance
Historical ComparisonAbout GROW U.S. Global Investors Inc.
US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.